Table 1.
Outcome results of major randomized phase III trials in the first-line setting in metastatic colorectal cancer patients
| Ref. | Regimen | n | Previous adjuvant treatment | ORR | Median PFS (mo) | Median OS (mo) | Post-study therapy |
| Hurwitz et al[80]Tebbutt et al[119] | IFL | 411 | 28% | 34.8% | 6.2 | 15.6 | 50% |
| Hurwitz et al[80] | IFL+bevacizumab | 402 | 24% | 44.8% | 10.6 | 20.3 | 50% |
| Cunningham et al[118] | Capecitabine | 140 | 18.6% | 10% | 5.1 | 16.8 | 37% |
| Capecitabine + bevacizumab | 140 | 32.1% | 19% | 9.1 | 20.7 | 37% | |
| Saltz et al[8] | XELOX/FOLFOX | 701 | 25%1 | 38% | 8 | 19.9 | 53% |
| XELOX/FOLFOX + bevacizumab | 699 | 24%1 | 38% | 9.4 | 21.3 | 46% | |
| Heinemann et al[81] | FOLFIRI + cetuximab | 297 | 22.1% | 62% | 10 | 28.7 | 65.7% |
| FOLFIRI + bevacizumab | 295 | 18.9% | 58% | 10.3 | 25 | 61.7% | |
| Capecitabine | 156 | 22% | 30.3% | 5.7 | 18.9 | 68% | |
| Tebbutt et al[119] | Capecitabine + bevacizumab | 157 | 28% | 38.1% | 8.5 | 18.9 | 62% |
| Capecitabine + bevacizumab + MMC | 158 | 16% | 45.9% | 8.4 | 16.4 | 61% | |
| Falcone et al[12] | FOLFOXIRI + bevacizumab | 252 | 12% | 65% | 12 | 31 | NA3 |
| FOLFIRI + bevacizumab | 256 | 12% | 53% | 9.7 | 25.8 | NA3 | |
| Van Cutsem et al[82] | FOLFIRI | 599 | 18.9% | 39.7% | 8.4 | 20 | 71.7% |
| FOLFIRI + cetuximab | 599 | 17.4% | 57.3% | 9.9 | 23.5 | 66% | |
| Maughan et al[91] | XELOX/FOLFOX2 | 815 | 25%1 | 57% | 8.6 | 17 | 62% |
| XELOX/FOLFOX + cetuximab | 815 | 25%1 | 64% | 8.6 | 17.9 | 56% | |
| Tveit et al[120] | FLOX | 185 | 8%1 | 41% | 7.9 | 20.4 | 73.5% |
| FLOX + cetuximab | 194 | 9%1 | 49% | 8.3 | 19.7 | 75.8% | |
| FLOX intermittently + cetuximab | 187 | 10%1 | 47% | 7.3 | 20.3 | 64.2% | |
| Douillard et al[90] | FOLFOX4 | 590 | 15%1 | 48% | 8 | 19.7 | 63% |
| FOLFOX4 + panitumumab | 593 | 16.1%1 | 55% | 9.6 | 23.9 | 53% | |
| Schmoll et al[89] | FOLFOX + bevacizumab | 713 | 19% | 47.3% | 10.3 | 21.3 | 23.8% |
| FOLFOX + cediranib | 709 | 17% | 46.3% | 9.9 | 22.8 | 28.2% | |
| Díaz-Rubio et al[60] | XELOX + bevacizumab | 239 | 13%1 | 47% | 10.4 | 23.2 | 72% |
| XELOX + bevacizumab→bevacizumab | 241 | 17%1 | 49% | 9.7 | 20 | 74% |
1
No previous oxaliplatin-based treatment allowed;
2
Both Arm A (continuously) and Arm B (intermittently) have been considered;
3
Data will be available in 2014. ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; IFL: Irinotecan, fluorouracil, leucovorin therapy; FOLFIRI: 5-fluorouracil and irinotecan; XELOX: Capecitabine/oxaliplatin.